Following the breakthrough license deal with Moderna, a global leader in mRNA therapeutics, in Q4’25, Nanexa now pursues two main tracks to ...
The announcement of Nanexa’s first licensing deal marks a meaningful validation of the PharmaShell platform, as Moderna, a global leader in ...
Nanexa’s Q3 report underscores a pivotal moment for the company.
Nanexa presented strong validation of its PharmaShell technology during the first half of 2025, with Phase I data showing once-monthly lirag...
Nanexa continues to strengthen the foundation for the upcoming Phase Ib/II study in the NEX-22 project, with preliminary PK data from the fi...
Nanexa’s Q4 report did not reveal much new, although the conference call provided welcome clarity on the rationale behind the extension of p...
With the directed issue of units amounting to SEK 35m, supplemented by SEK 20m in loans, Nanexa secures funding for its continued developmen...
The positive results in Nanexa’s Phase I study for NEX-22, a once-monthly depot formulation of the GLP-1 analog liraglutide for type 2 diabe...
NEX-22 is progressing as expected, with the last patient in Phase I treated, results anticipated later in November, and Phase IIb scheduled ...
After initiating dosing of the first patient in June with Nanexa’s long-acting depot formulation of the GLP-1 analog liraglutide, NEX-22 for...
Redeye updates its view of Nanexa following the Q1 report and recent events in the company, including the CMD earlier this week, which offer...
Apart from a slight further delay in the start of Phase I with NEX-22, the report for Q1’24 proved rather uneventful.
Redeye notes that Nanexa’s Q1 report offered no material surprises, with revenues at SEK7.
Muted quarter with work in progress NEX-22 Ph 1 approval and start exp.
Redeye updates its view of Nanexa following the Q4 report and recent events in the company.
Apart from a write down of capitalized development related to the suspended projects NEX-18 and NEX-20, there was not much new in Nanexa’s f...
NEX-22 start potentially delayed into Q2'24e (Q1'24e) Next milestone: NEX-22 Ph 1 approval Webcast today at 11:30 CET Relevant events durin...
Following the focusing of the roadmap after the rights issue in October, Nanexa has now announced a further streamlining of its activities t...
Redeye comments on the news that Nanexa has decided to focus its business on three key areas, which, combined with cost savings, will extend...
Short/medium term priorities: NEX-22, Novo and partner projects NEX-18 and NEX-20 on hold NEX-22 Ph 1 CTA assessed by EMA; Ph 1 start in Q1'...
Redeye endorses today’s news that Nanexa has signed an evaluation agreement with a global pharma company regarding using Pharmashell to deve...
Signs evaluation agreement with "large global pharma company" To evaluate PharmaShell in depot formulation of monoclonal antibody Not a new ...
Redeye updates its view of Nanexa following the Q3 report and recent events in the company.
With the dust settling after the recent rights issue, Nanexa now progresses with its more focused roadmap, concentrating on Phase I trials w...
No material updates in Q3 report Next material milestone: NEX-22 Ph 1 study in type 2 diabetes Webcast today at 15:00 CET Relevant events d...
SEK 75m from rights issue leads to project re-prioritisation Primary focus on GLP-1 RA space (NEX-22 & Novo Nordisk collab.
With a subscription rate of 34.7% of the rights issue, and a utilization of guarantee commitments corresponding to 27.
Redeye comments on the outcome of Nanexa’s rights issue, that resulted in a subscription rate of 34.
Redeye comments on Nanexa’s preliminary key financial information for Q3.
With the recently completed Phase 1 study for NEX-20 yielding positive results, and the widespread global interest in GLP-1, Nanexa now has ...
Provides updated development plan at investor meeting Detailed path forward for different rights issue outcomes NEX-22: CTA submission in Q4...
NEX-20 Ph 1 study in multiple myeloma completed Mild to moderate local skin reactions; new formulation under development Investor meeting ne...
Redeye is encouraged by the announcement that Nanexa’s clinical phase I trial with NEX-20 (NEX-20-01), a long-acting formulation of lenalido...
Rights issue of SEK 121m; subscription period: 12-26 Oct Use of proceeds could finance operations well into '25 67% dilution; new fair value...
As we had expected, Nanexa announced a SEK 121m rights issue, albeit at a slightly higher than expected both discount and amount.
Redeye comments on Nanexa’s rights issue that was announced earlier today.
We provide a fresh look at Nanexa's prospects GLP-1 receptor agonists a good space to focus efforts Updated valuation with new fair value ra...
Redeye comments on Nanexa’s Q2 2023 report and endorses the company’s recent progress related to NEX-20 and NEX-22.
Nanexa’s Q2’23 advancements with NEX-20 and NEX-22 underscore the company’s forward momentum.
Outlook focus on NEX-22 with Ph1 start in early '24e Positive initial NEX-20 Ph1 PK reported yesterday Live commentary today at 11:00 CET R...
PK data for NEX-20 confirms slow-release of lenalidomide Results in line with preclinical studies Nanexa will report Q2 tomorrow at 08:00 CE...
Redeye endorses the positive results from Nanexa’s clinical phase I trial with NEX-20, a long-acting formulation of lenalidomide.
Redeye reviews the Nanexa case in light of the recent development of NEX-20, its latest project NEX-22, and its collaboration with Novo Nord...
After positive pre-clinical results in rats with NEX-22 (for treatment of type 2 diabetes) in Q1, we now see results from phase I for NEX-20...
No material updates in the Q1 report NEX-20 Ph 1 study completed by June '23e Live commentary today at 15:00 CET Events during the quarter ...
Redeye comments on Nanexa’s Q1 report and notes important key activities carried out in the quarter.
Redeye return with a research update following the Q4 report and recent progress in the company.
After a news packed Q4 2022, including an exclusivity and evaluation agreement with Novo Nordisk, start of Phase I with NEX-20 and two addit...
Neutral reaction expected to uneventful report NEX-20 in the clinic, no news on NEX-18 timelines Live commentary today at 14:00 CET A quart...
Redeye is impressed and relieved by yesterday’s news that Nanexa has signed an exclusivity- and evaluation agreement with Novo Nordisk worth...
Redeye has a mildly positive take on today’s news that Nanexa has reached a settlement with Vitrivax.
Redeye comments on Nanexa’s Q3 report and our view the of progress in the quarter.
Encouraging progress on BD, litigation, and clinical front Opens for making NEX-18 superior to Vidaza Co.
Redeye is cautiously optimistic about today’s update from Nanexa’s patent infringement case, indicating that the parties (Nanexa and Vitriva...
Redeye gives a short comment on Nanexa’s new project: NEX-22.
NEX-22: Liraglutide for type 2 diabetes (T2D) Liraglutide (Novo’s Victoza) DKK 15bn in 2021 Preclinical studies ongoing, clinical trial ex...
Redeye endorses today’s news that Nanexa has signed an evaluation agreement with a global pharmaceutical company, that also includes an opti...
Redeye comments on the Q2 report from Nanexa, which came in more or less as expected.
New facility receives GMP certification Developed first formulations with mAbs Neutral share price reaction expected today New facility GMP ...
New pilot plant lays foundation for licensing agreements NEX-18 programme pause pushes approvals to ‘28 Updated valuation with new fair val...
Redeye gives a short comment on today’s news and reiterate our view of Nanexa.
Covers manufacturing method and resulting products Good timing with recent completion of new plant Raises appeal of PharmaShell for potenti...
Redeye comments on Nanexa’s Q1 report and give our view of progress so far in 2022.
We give a short comment on the progress in Nanexa's patent infringement case.
Redeye comments on Nanexa's Q4 report and summarize our view of progress in 2021.
Redeye comments on today’s update on the NEX-18 clinical program.
We give a brief comment on today’s news that Nanexa has received orders worth in total SEK 1.
Redeye maintains its view of Nanexa and base case of SEK 9.
